Satellos Bioscience Inc. (MSLE) Stock

About Satellos Bioscience Inc.

Satellos Bioscience Inc. is led by CEO Francis Gleeson, employs 14 people, headquartered in CA, publicly traded since 2024.

Satellos Bioscience Inc. (MSLE) stock trades at $6.42 with a market capitalization of $8.27M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.26, reflecting a net loss over the last twelve months, price-to-book of 2.93, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.30 and $13.39, and currently trades 52.1% below its 52-week high.

On profitability, Satellos Bioscience Inc. generates a return on equity (ROE) of -72.67% (negative, reflecting a net loss), return on capital employed of -60.09%.

Satellos Bioscience Inc. by the numbers, 2015–2025

Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-25.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-34.0M.

Borrowings stand at $0, cash from operations was $-24.0M in the latest year, positive in 0 of the last 11.

Return on equity has averaged -145.6% over five years, and was -89.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Satellos Bioscience Inc. (MSLE) — frequently asked questions